Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Microbot Medical Inc
(NQ:
MBOT
)
0.8800
-0.0400 (-4.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Microbot Medical Inc
< Previous
1
2
3
Next >
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
August 22, 2024
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
August 13, 2024
The ISO 13485 certification is a validation of the Company’s robust quality system
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System
August 01, 2024
The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center
July 18, 2024
As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women’s Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trial
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial
July 09, 2024
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial
July 08, 2024
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial
July 03, 2024
Following the Company’s recent FDA approval to commence its pivotal human clinical trial, Baptist Hospital of Miami is the second clinical site to enroll in the trial
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial
June 20, 2024
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial
June 17, 2024
The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was delivered
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
June 04, 2024
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
June 03, 2024
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
June 03, 2024
The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular Robotic Surgical System, which together are expected to support a future 510(k)...
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
April 29, 2024
The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular procedures
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Shares Status Following Recent Geopolitical Events
April 15, 2024
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
February 05, 2024
The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this application
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
January 30, 2024
All of the cash payable to the plaintiffs in the settlement will be covered by Microbot’s insurance carrier and will not impact company's cash position
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
January 18, 2024
Following the recent positive results of its pivotal GLP pre-clinical study, the Company added a CRA to facilitate the company's first in human clinical study
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
December 29, 2023
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
December 28, 2023
The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic
December 14, 2023
The first phase in the collaboration will evaluate the current state of the LIBERTY® Robotic Surgical System in connection with remote enabled Endovascular treatments
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study
December 07, 2023
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities
November 21, 2023
The former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the clinical and regulatory phase.
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process
November 13, 2023
The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with the FDA
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office
November 08, 2023
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study
October 31, 2023
Follow up visual examination three days after the procedures using the LIBERTY Robotic Surgical System, confirms 100% success rate in reaching the targets with no adverse events
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Received Confirmation for the Commencement of Its CE Mark Approval Process During the First Half of 2024
October 24, 2023
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company
October 19, 2023
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY® Robotic Surgical System
October 17, 2023
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Engages CRO to Support its Upcoming U.S. Pivotal Clinical Trial
September 27, 2023
The engagement is an additional step in the Company's path towards marketing clearance with the FDA
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023
September 08, 2023
The presentation follows successful extensive uses of the Company’s endovascular robotic system in pre-clinical studies
From
Microbot Medical Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.